Janus Henderson Group’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Janus Henderson Group’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-52,917	Closed	-$524K	–	2659
2022 Q2	$524K	Hold	52,917	–	–	﹤0.01%	1733
2022 Q1	$523K	Hold	52,917	–	–	﹤0.01%	1895
2021 Q4	$516K	Buy	52,917 +6,318	+14%	+$63K	﹤0.01%	1875
2021 Q3	$464K	Hold	46,599	–	–	﹤0.01%	1652
2021 Q2	$467K	Buy	46,599 +26,599	+133%	+$266K	﹤0.01%	1442
2021 Q1	$198K	Buy	+20,000	New	+$200K	﹤0.01%	1509

Other funds holding IBER.U

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Janus Henderson Group's IBER.U Position: Q3 2022 in Review

Janus Henderson Group sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q3 2022, closing a stake of 52,917 shares — an estimated $524K sold.

Janus Henderson Group first reported a position in IBER.U in Q1 2021 and held it in 6 quarters. The position peaked at $524K in Q2 2022. 13 funds tracked by Wall St. Rank hold IBER.U as of Q3 2022.

Janus Henderson Group reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q3 2022 after selling out during the quarter.
Janus Henderson Group sold 52,917 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2022, an estimated $524K.
Janus Henderson Group first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 6 quarters.
Janus Henderson Group's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $524K in Q2 2022.
13 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2022.

Based on Janus Henderson Group's 13F filing for Q3 2022, filed 14 Nov 2022.